Seres Therapeutics, Inc. (MCRB): Roger Pomerantz , President and CEO of Seres Therapeutics, Inc. sold 9,212 shares on Apr 7, 2016. The Insider selling transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were sold at $30.00 per share for a total value of $276,360.00.
Company has been under the radar of several Street Analysts.Seres Therapeutics Inc is Initiated by FBR Capital to Outperform and the brokerage firm has set the Price Target at $40. The Rating was issued on Mar 30, 2016.Seres Therapeutics Inc is Initiated by Guggenheim to Buy. The Rating was issued on Mar 3, 2016.Seres Therapeutics Inc is Initiated by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $55. The Rating was issued on Jan 25, 2016.
Institutional Investors own 74.94% of Seres Therapeutics Inc shares.
Shares of Seres Therapeutics Inc (MCRB) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.73 points or -2.36% at $30.25 with 1,67,016 shares getting traded. Post opening the session at $30.84, the shares hit an intraday low of $29.75 and an intraday high of $30.95 and the price vacillated in this range throughout the day. The company has a market cap of $1,185 M and the number of outstanding shares has been calculated to be 3,91,87,017 shares. The 52-week high of Seres Therapeutics Inc is $52 and the 52-week low is $21.12.
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.